Anatomical Integrity Mapping (AIM): Non-invasive imaging driven patient identification, prognosis and stratification in dementia

In healthcare, the timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. Rapid correct diagnosis is key in unlocking personalised approaches for degenerative diseases like dementia and fibrosis where stratification is mandatory for correct treatment. Early detection of these diseases would result in a significantly improved patient prognosis but there is a dearth of diagnostic options in these indications. AINOSTICS' technology represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis of tissue modifying diseases using multi-modal imaging and non-imaging MRI data; useful for both the treatment of patients and the development of therapeutics. AINOSTICS' technology can automatically and intelligently analyse scans to provide sensitive and accurate micro-structural information about key tissue and organ structures then compare this with information from healthy populations to detect the signatures of disease. We intend AINOSTICS' software to become a routine part of clinical practice and drug development as the results of our intelligent analysis will provide clinicians, researchers, and imaging centres a convenient and cost-effective means to get reliable and objective diagnostic data needed to inform on patient disease status. For serious global diseases, software AINOSTICS' technology has the potential to save time during patient assessments, accelerate clinical pathways, standardise the quality of care and improve patient outcomes in addition to making important contributions to the development of disease modifying therapeutics.